NASDAQ:HOTH - US44148G2049 - Common Stock
The current stock price of HOTH is 1.465 USD. In the past month the price increased by 23.11%. In the past year, price increased by 33.18%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 44.58 | 681.47B | ||
JNJ | JOHNSON & JOHNSON | 17.84 | 429.61B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 18.24 | 251.05B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 14.55 | 249.29B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 14.01 | 243.39B | ||
MRK | MERCK & CO. INC. | 10.88 | 209.29B | ||
PFE | PFIZER INC | 7.24 | 139.49B | ||
SNY | SANOFI-ADR | 10.46 | 113.23B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.88 | 94.20B | ||
GSK | GSK PLC-SPON ADR | 8.82 | 80.27B | ||
ZTS | ZOETIS INC | 24.48 | 67.49B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 52 | 47.63B |
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2019-02-15. The firm is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The firm also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).
HOTH THERAPEUTICS INC
1177 Avenue Of The Americas, 5Th Floor Suite 5066
New York City NEW YORK 10020 US
CEO: Robb Knie
Employees: 3
Phone: 16467562997
The current stock price of HOTH is 1.465 USD. The price increased by 10.15% in the last trading session.
The exchange symbol of HOTH THERAPEUTICS INC is HOTH and it is listed on the Nasdaq exchange.
HOTH stock is listed on the Nasdaq exchange.
7 analysts have analysed HOTH and the average price target is 4.08 USD. This implies a price increase of 178.5% is expected in the next year compared to the current price of 1.465. Check the HOTH THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
HOTH THERAPEUTICS INC (HOTH) has a market capitalization of 19.43M USD. This makes HOTH a Nano Cap stock.
HOTH THERAPEUTICS INC (HOTH) currently has 3 employees.
HOTH THERAPEUTICS INC (HOTH) has a support level at 1.29 and a resistance level at 1.48. Check the full technical report for a detailed analysis of HOTH support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
HOTH does not pay a dividend.
HOTH THERAPEUTICS INC (HOTH) will report earnings on 2025-11-10, after the market close.
HOTH THERAPEUTICS INC (HOTH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.07).
The outstanding short interest for HOTH THERAPEUTICS INC (HOTH) is 2.01% of its float. Check the ownership tab for more information on the HOTH short interest.
ChartMill assigns a technical rating of 8 / 10 to HOTH. When comparing the yearly performance of all stocks, HOTH is one of the better performing stocks in the market, outperforming 81.88% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to HOTH. No worries on liquidiy or solvency for HOTH as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months HOTH reported a non-GAAP Earnings per Share(EPS) of -1.07. The EPS increased by 33.95% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -100.8% | ||
ROE | -104.57% | ||
Debt/Equity | 0 |
7 analysts have analysed HOTH and the average price target is 4.08 USD. This implies a price increase of 178.5% is expected in the next year compared to the current price of 1.465.